Background & objectives.  Over the past decade, the prevalence of COPD became critical due to the environmental degradation and widespread tobacco smoking among Ukrainian population, and thus has become one of the leading causes of death. Immunodeficiency, caused by the development of systemic inflammatory reaction, plays an important role in worsening of COPD course.

Aims and objectives to evaluate the effect of roflumilast on the dynamics of TNF?, IL-1? levels in bronchoalveolar lavage of stable COPD patients.

Methods. The investigation dealt with the study of ?NF?, IL-1? levels in 61COPD patients GOLD ??? while introducing roflumilast medication as part of their complex therapy. Experimental group ? involved 12 patients, who were treated with standard methods, excluding roflumilast, according to GOLD recommendations; group ??-a ? included 23 patients, who were additionally administered roflumilast orally, 500 mcg, once per day for 30 days; group ??-b - 15 patients, with additionally 500 mcg of roflumilast orally for 90 days; group II-c - 11patients, who were additionally administered 500 mcg roflumilast orally daily for 180 days. The control group included 15 apparently healthy individuals (AHI).

Results. The research findings show that both groups I and II do not provide complete elimination of disorders in interleukin system. Prolonged usage of roflumilast for 3-6 months, contributed to the normalization of proinflammatory cytokines levels.

Conclusions. Prolonged administration of roflumilast for 180 days, as part of complex therapy, contributed greatly to the restoration of physiological values of the studied cytokines.